What an amazing story. This is #WhyWeEKOS
#EvidenceBasedMedicine #HIPEITHO PERT Consortium

#Gaming companies: What are the benefits of accepting payments in points? 5 key takeaways from conversation with Xsolla chief marketing officer Berkley Egenes 🎮 🕹️ and Mastercard SVP Jen Premisler. #SXSW #ad bit.ly/40pxXwb

Want to decrease your impact on the environment while using a laptop? Here are ten easy-to-implement green habits you can develop as a laptop owner. Click the post to learn more!

#whyweEKOS

(1/13) EKOS Catheter Insertion Tweetorial.
Mustafa Ahmed Mouhamed Amr Sabouni MD Sam McElwee
My cofellows Muhannad Almubarak Ali Ebrahimi

UAB Cardiovascular Disease UAB Cardiovascular Institute #WIN

#DYK EKOS was the 1st interventional device approved for the treatment of PE? Since then, over 75,000 patients have been treated. Tag me in your #whyweEKOS cases.

Congrats to the HI-PEITHO study team at Cardiology Associates Research and North Mississippi Medical Center for enrolling their first patient! #EvidencedBasedMedicine #WhyWeEkos Boston Scientific DR MICHAEL R JAFF kenneth rosenfield Fionnuala Ní Áinle Erik Klok Andrew SP Sharp North Mississippi Medical Center

With the current global #contrastshortage , Dr. Anas Safadi, MD shares his contrast-free technique using CTA as a roadmap for #EKOS catheter placement for the treatment of #PE . Learn more in this 10-minute video: bit.ly/3xVMt3A #WhyWeEKOS

Presented at #VENOUS2023 1036 #PE patients analyzed for in-hosp mortality showed #EKOS demonstrated a significantly lower rate, at any lytic dose, compared to those treated with mechanical thrombectomy. #WhyWeEKOS #EvidenceBasedMedicine bit.ly/3IxB3r3

Excited to see that in recognition of the strong clinical evidence supporting its use dissolving clot in the deep venous system, the FDA has granted the EKOS indication for the treatment of #DVT . #EKOS #WhyWeEKOS #EvidenceBasedMedicine
bit.ly/3E1EvWv

#EKOS #WhyWeEKOS

How have I only just realised?

Congratulations to the team at the University Medical Center of the Johannes Gutenberg University of Mainz for enrolling the first #HIPEITHO patient in Germany! Mainz University Boston Scientific Jeff Mirviss DR MICHAEL R JAFF kenneth rosenfield Andrew SP Sharp Erik Klok Fionnuala Ní Áinle #WhyWeEkos

We #EKOS because our device is the most studied device in the PE space and the only interventional device to treat PE with long-term data. Learn more about #whyweEKOS : bit.ly/2VKyqh2

bit.ly/2ZPw3rJ

Ever see data that makes you think: Hmmmm? Presented at #ISET2023 911 #PE pts analyzed for Hosp LOS showed mechanical thrombectomy had a 51% longer hospital stay than #EKOS . #WhyWeEKOS #EvidenceBasedMedicine Keith Sterling

#WhyWeEKOS ; a prescribed protocol that allows for predictable procedural workflow and proven patient outcomes. #PE #EKOS #EvidenceBasedMedicine
Learn more: bit.ly/3tB1AMv

[BS: bit.ly/31iSo1d]

Visit BSC at booth 109 today to hear more about #Varithena and EKOS+. Venous Symposium #WhyWeEKOS #VenousSymposium2023

“We were that close – just a day or so – from getting on an airplane, getting on a cruise. I wouldn’t have survived. There’s no way. And to have the kind of help available right here near our home meant the world to us.”

STORY: bestcare.org/news/20220824/…

#HIPEITHO #clinicaltrials

Welcome to #HIPEITHO Erik Klok and study team at LUMC Leiden! The first site to open in The Netherlands! We look forward to your first enrollment! Boston Scientific Jeff Mirviss DR MICHAEL R JAFF Andrew SP Sharp Fionnuala Ní Áinle kenneth rosenfield #Ekos #WhyWeEkos #EvidencedBasedMedicine

EKOS is a safe, repeatable and reliable treatment that dissolves thrombus quickly with low lytic, low blood loss and low trauma – resulting in proven long-term outcomes.  #evidencebasedmedicine #whyweEKOS #pulmonaryembolism #ekostherapy #BSCEMEA bit.ly/39VAQQW